Related references
Note: Only part of the references are listed.Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy
Scott D. Solomon et al.
CIRCULATION (2009)
Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry
Raghava S. Velagaleti et al.
CIRCULATION (2008)
Role of aldosterone in left ventricular hypertrophy in hypertension
K Matsumura et al.
AMERICAN JOURNAL OF HYPERTENSION (2006)
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
RB Devereux et al.
CIRCULATION (2004)
Prognostic significance of left ventricular mass change during treatment of hypertension
RB Devereux et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events
PM Okin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy - The 4E-left ventricular hypertrophy study
B Pitt et al.
CIRCULATION (2003)
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
AU Klingbeil et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Pathophysiological effects of aldosterone in cardiovascular tissues
R Rocha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2001)
Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy
A Sato et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2001)
Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension
G Schillaci et al.
HYPERTENSION (2000)
Share Paper
